Ikonisys Inc has been awarded a multi-year, multi-unit contract by NeoGenomics Laboratories to procure and deploy the Ikoniscope/IkoniLAN robotic microscopy platform.
"We’re very pleased to broaden our relationship with NeoGenomics," says Petros Tsipouras, PhD, chairman and CEO of Ikonisys. "We look forward to working with their team to engage the capabilities of our world-class microscopy platform for their cancer diagnostic needs."
Robert Gasparini, president and chief scientific officer of NeoGenomics Laboratories, says, "The Ikonisys robotic microscope truly represents the next generation of FISH (fluorescence in-situ hybridization) analysis automation by allowing previously unreachable analytical sensitivities. We are excited to be the first cancer diagnostic company to fully integrate the Ikonisys robotic microscopy platform into our service."
Ikonisys has developed the Ikoniscope/IkoniLAN, a robotic microscopy system for fully automated, high-throughput signal detection and analysis. In February 2006 the company announced that the United States Food and Drug Administration (FDA) cleared for marketing in the United States its automated cell-locating device, the Ikoniscope fastFISH amnio test system. The company is developing several products and applications for cancer prenatal diagnosis/screening based on the utilization of its robotic microscopy system.